Drug profile · INN
azacitidine
AZACITIDINE ACCORD
azacitidine (AZACITIDINE ACCORD) is a dna (cytosine-5)-methyltransferase 3a inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — azacitidine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 20
- Programs
- 58
- Data quality
- 0.89
Quick answer
azacitidine (AZACITIDINE ACCORD) is a dna (cytosine-5)-methyltransferase 3a inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA (cytosine-5)-methyltransferase 3A inhibitor
Primary target: DNA (cytosine-5)-methyltransferase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Congress & event coverage
- PresentationDIA
- PresentationTHMA Pharmacy Growth
Pipeline programs
Related & competitor drugs
Related patents
-
US 12428406
Methods and compounds for restoring mutant p53 function
granted -
US 12419880
Companion diagnostic tool for mutant p53 reactivating compounds
granted -
WO 2025027051
INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
granted -
WO 2024211523
SCHÉMAS POSOLOGIQUES DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION DE LA RECHUTE DE LA LEUCÉMIE MYÉLOÏDE AIGUË APRÈS UNE TRANSPLANTATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ALLOGÉNIQUES AVEC DU VÉNÉTOCLAX EN COMBINAISON AVEC DE L'AZACITIDINE
granted -
WO 2024175803
COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES
granted -
WO 2024146923
INHIBITEURS DE POLYMÉRISATION DE TUBULINE
granted -
US 11963953
Deuterated compounds for restoring mutant p53 function
granted -
US 11926632
Methods and compounds for restoring mutant p53 function
granted -
US 11814373
Methods and compounds for restoring mutant p53 function
granted -
US 11807644
Methods and compounds for restoring mutant p53 function
granted -
US 11731953
Methods and compounds for restoring mutant p53 function
granted -
WO 2022234069
NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
granted -
US 11339141
Methods and compounds for restoring mutant p53 function
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 10640485
Methods and compounds for restoring mutant p53 function
granted -
US 10138219
Methods and compounds for restoring mutant p53 function
granted -
EP 3144307
NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER
granted -
EP 3027208
DIAGNOSE UND THERAPIE VON KREBS MIT KREBSSTAMMZELLEN
granted -
WO 2016085391
DÉRIVÉS DE BIS (SULFONAMIDE) ETLEUR UTILISATION COMME INHIBITEURS DE MPGES
granted
Frequently asked questions
What is azacitidine?
azacitidine (AZACITIDINE ACCORD) is a dna (cytosine-5)-methyltransferase 3a inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for azacitidine?
AZACITIDINE ACCORD is a marketed brand name for azacitidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of azacitidine?
azacitidine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.